Erratum: Ranolazine Effectively Suppresses Atrial Fibrillation in the Setting of Heart Failure. (Circ Heart Fail. 2014; 7 (627-633)) DOI: 10.1161/CIRCHEARTFAILURE.114.001129;Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure

Circulation: Heart Failure

Volumn 7, Issue 4, 2014, Pages 627-633

  Burashnikov, Alexander ^a   Di Diego, José M ^a   Barajas Martínez, Hector ^a   Hu, Dan ^a   Cordeiro, Jonathan M ^a   Moise, N Sydney ^b   Kornreich, Bruce G ^b   Belardinelli, Luiz ^c   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b Cornell University ^*  (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Anti arrhythmia agents; Arrhythmias, cardiac; Electrophysiology; Pharmacology; Sodium channel blockers

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; RANOLAZINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; ACETANILIDE DERIVATIVE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE;

ACTION POTENTIAL; ACTION POTENTIAL DURATION; ADULT; ARTICLE; ATRIAL FIBRILLATION; DRUG SAFETY; ELECTROPHYSIOLOGY; EXTRASYSTOLE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE POTENTIAL; MICROELECTRODE; MIDDLE AGED; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; DOG; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ELECTROPHYSIOLOGY; PHARMACOLOGY; SODIUM CHANNEL BLOCKERS;

ACETANILIDES; ACTION POTENTIALS; ANIMALS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HEART ATRIA; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART VENTRICLES; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PIPERAZINES; SODIUM CHANNEL BLOCKERS;

EID: 84907380995     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/HHF.0000000000000008     Document Type: Erratum

References (34)

1. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J. 2013;34:1471-1474.
2. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs. 2009;69:757-774.
3. Burashnikov A, Antzelevitch C. Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther. 2011;132:300-313.
4. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-1457.
5. Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol. 2009;20:796-802.
6. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95.
7. Cordeiro JM, Calloe K, Moise NS, Kornreich B, Giannandrea D, Di Diego JM, Olesen SP, Antzelevitch C. Physiological consequences of transient outward K+ current activation during heart failure in the canine left ventricle. J Mol Cell Cardiol. 2012;52:1291-1298.
8. Burashnikov A, Di Diego JM, Sicouri S, Doss MX, Sachinidis A, Barajas-Martínez H, Hu D, Minoura Y, Sydney Moise N, Kornreich BG, Chi L, Belardinelli L, Antzelevitch C. A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. Eur J Heart Fail. 2014;16:271-280.
9. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910.
10. Zygmunt AC, Nesterenko VV, Rajamani S, Hu D, Barajas-Martinez H, Belardinelli L, Antzelevitch C. Mechanisms of atrial-selective block of Na+ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol. 2011;301:H1606-H1614.
11. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216-1224.
12. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17(suppl 1):S169-S177.
13. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8:1281-1290.
14. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 Suppl 4:iv6-iv14.
15. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
16. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non STsegment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-1652.
17. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007;49:1027-1034.
18. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310:599-605.
19. Antoons G, Oros A, Beekman JD, Engelen MA, Houtman MJ, Belardinelli L, Stengl M, Vos MA. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010;55:801-809.
20. Kirchhof PF, Fabritz CL, Franz MR. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. Circulation. 1998;97:2567-2574.
21. Burashnikov A, Belardinelli L, Antzelevitch C. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther. 2012;340:161-168.
22. Burashnikov A, Di Diego JM, Sicouri S, Ferreiro M, Carlsson L, Antzelevitch C. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 2008;5:1735-1742.
23. Frommeyer G, Schmidt M, Claus C, Kaese S, Stypmann J, Pott C, Eckardt L, Milberg P. Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur J Heart Fail. 2012;14:1322-1331.
24. Suzuki T, Morishima M, Kato S, Ueda N, Honjo H, Kamiya K. Atrial selectivity in Na+channel blockade by acute amiodarone. Cardiovasc Res. 2013;98:136-144.
25. Murdock DK, Reiffel JA, Kaliebe J, Larrian G. The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: implications for a new "pill-in-pocket" approach in structural heart disease. J Atr Fibrillation. 2010;2:705-710.
26. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673-676.
27. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol. 2010;3:88-95.
28. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J Suppl. 2006;8:A10-A13.
29. Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311-323.
30. Undrovinas NA, Maltsev VA, Belardinelli L, Sabbah HN, Undrovinas A. Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. J Physiol Sci. 2010;60:245-257.
31. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley SC Jr. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110:841-850.
32. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, Jacobshagen C. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. J Am Coll Cardiol Heart Fail. 2013;1:115-122.
33. Rosenberg MA, Gottdiener JS, Heckbert SR, Mukamal KJ. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J. 2012;33:904-912.
34. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a populationbased study. N Engl J Med. 2006;355:260-269.